Natalya Danchenko

2.1k total citations · 1 hit paper
62 papers, 1.5k citations indexed

About

Natalya Danchenko is a scholar working on Pharmacology, Neurology and Psychiatry and Mental health. According to data from OpenAlex, Natalya Danchenko has authored 62 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pharmacology, 20 papers in Neurology and 19 papers in Psychiatry and Mental health. Recurrent topics in Natalya Danchenko's work include Treatment of Major Depression (21 papers), Botulinum Toxin and Related Neurological Disorders (20 papers) and Cerebral Palsy and Movement Disorders (11 papers). Natalya Danchenko is often cited by papers focused on Treatment of Major Depression (21 papers), Botulinum Toxin and Related Neurological Disorders (20 papers) and Cerebral Palsy and Movement Disorders (11 papers). Natalya Danchenko collaborates with scholars based in United States, France and United Kingdom. Natalya Danchenko's co-authors include Jessie A. Satia, Mary S. Anthony, Susan Manzi, Kathleen Gondek, Amy Kao, David Thompson, C. François, Kathleen Lang, Sonalee Shah and Joseph M. Ahearn and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Natalya Danchenko

58 papers receiving 1.5k citations

Hit Papers

Epidemiology of systemic lupus erythematosus: a compariso... 2006 2026 2012 2019 2006 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden
    2006 574 citations Natalya Danchenko et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Natalya Danchenko United States 19 739 522 266 172 151 62 1.5k
Ron Pedersen United States 25 1.0k 1.4× 558 1.1× 211 0.8× 128 0.7× 83 0.5× 55 1.8k
Uzma Haque United States 15 469 0.6× 245 0.5× 259 1.0× 82 0.5× 51 0.3× 29 1.5k
Ramesh K. Gupta India 20 320 0.4× 197 0.4× 186 0.7× 58 0.3× 173 1.1× 74 1.4k
Johannes W G Jacobs Netherlands 23 1.2k 1.6× 160 0.3× 184 0.7× 55 0.3× 174 1.2× 62 2.0k
Enrico Fusaro Italy 22 293 0.4× 181 0.3× 199 0.7× 60 0.3× 45 0.3× 84 1.2k
Cristina Iannuccelli Italy 23 497 0.7× 217 0.4× 234 0.9× 10 0.1× 107 0.7× 58 1.5k
Shmuel Tiosano Israel 24 454 0.6× 236 0.5× 176 0.7× 10 0.1× 48 0.3× 84 1.6k
Sofia Pedro United States 16 488 0.7× 111 0.2× 43 0.2× 50 0.3× 21 0.1× 38 954
Y. Brault France 16 228 0.3× 176 0.3× 38 0.1× 33 0.2× 35 0.2× 48 1.6k
Pedro Zarco Spain 26 1.1k 1.4× 679 1.3× 74 0.3× 140 0.8× 379 2.5× 173 2.5k

Countries citing papers authored by Natalya Danchenko

Since Specialization
Citations

This map shows the geographic impact of Natalya Danchenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natalya Danchenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natalya Danchenko more than expected).

Fields of papers citing papers by Natalya Danchenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natalya Danchenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natalya Danchenko. The network helps show where Natalya Danchenko may publish in the future.

Co-authorship network of co-authors of Natalya Danchenko

This figure shows the co-authorship network connecting the top 25 collaborators of Natalya Danchenko. A scholar is included among the top collaborators of Natalya Danchenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natalya Danchenko. Natalya Danchenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hüll, Michael, et al.. (2023). Health care resource utilization and costs among patients with spasticity or cervical dystonia. Journal of Managed Care & Specialty Pharmacy. 30(1). 86–97. 3 indexed citations
3.
4.
Atsou, Kokuvi, Larry Ereshefsky, Mélanie Brignone, et al.. (2020). Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant. Expert Review of Pharmacoeconomics & Outcomes Research. 21(1). 29–42. 2 indexed citations
5.
Schnitzler, Alfons, et al.. (2020). PND13 NETWORK META-ANALYSIS FOR BOTULINUM TOXIN A FOR THE TREATMENT OF ADULT LOWER LIMB SPASTICITY (ALLS) IN POST-STROKE POPULATION. Value in Health. 23. S260–S260. 1 indexed citations
6.
Johnston, Karissa, Natalya Danchenko, & Jonas Lundkvist. (2020). PND34 RESOURCE USE RELATED TO CERVICAL DYSTONIA, PEDIATRIC LOWER LIMB SPASTICITY AND ADULT UPPER LIMB SPASTICITY IN THE UNITED KINGDOM: A PHYSICIAN QUESTIONNAIRE. Value in Health. 23. S265–S265. 1 indexed citations
7.
8.
Thase, Michael E., Natalya Danchenko, Mélanie Brignone, et al.. (2017). Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology. 27(8). 773–781. 21 indexed citations
9.
Soini, Erkki, Taru Hallinen, Mélanie Brignone, et al.. (2016). Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Review of Pharmacoeconomics & Outcomes Research. 17(3). 293–302. 18 indexed citations
10.
Danchenko, Natalya, et al.. (2016). Cost-Effectiveness Evaluation of Vortioxetine in Major Depressive Episode in the UK Setting. Value in Health. 19(7). A525–A525.
11.
12.
Fehnel, Sheri, Barbara Forsyth, Dana DiBenedetti, et al.. (2013). Patient-centered assessment of cognitive symptoms of depression. CNS Spectrums. 21(1). 43–52. 66 indexed citations
13.
Lam, Raymond W., et al.. (2013). Psychometric Validation of Perceived Deficits Questionnaire – Depression (PDQ-D) in Patients with Major Depressive Disorder (MDD). Value in Health. 16(7). A330–A330. 37 indexed citations
14.
Florea, Ioana, et al.. (2013). The effect of vortioxetine (LU AA21004) on health-related quality of life (HRQOL) in patients with major depressive disorder (MDD). Value in Health. 16(3). A65–A65. 1 indexed citations
15.
Nordström, G., Natalya Danchenko, Nicolas Despiégel, & Florence Marteau. (2012). Cost-Effectiveness Evaluation in Sweden of Escitalopram Compared with Venlafaxine Extended-Release as First-Line Treatment in Major Depressive Disorder. Value in Health. 15(2). 231–239. 7 indexed citations
16.
Nordström, G., Nicolas Despiégel, Florence Marteau, Natalya Danchenko, & Khaled Maman. (2010). Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. Journal of Medical Economics. 13(3). 516–526. 10 indexed citations
17.
Xie, Feng, Nicolas Despiégel, Natalya Danchenko, & Karina Hansen. (2008). Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice. 13(1). 59–69. 3 indexed citations
18.
Danchenko, Natalya. (2007). Cost-Effectiveness of Escitalopram Versus Citalopram and Venlafaxine in Treatment of Severe Depression in Norway. SSRN Electronic Journal. 2 indexed citations
19.
Liu, Chau‐Ching, Susan Manzi, Natalya Danchenko, & Joseph M. Ahearn. (2004). New advances in measurement of complement activation: Lessons of systemic lupus erythematosus. Current Rheumatology Reports. 6(5). 375–381. 19 indexed citations
20.
Manzi, Susan, J Navrátil, Natalya Danchenko, et al.. (2004). Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis & Rheumatism. 50(11). 3596–3604. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ron Pedersen Breakdown of academic impact, for papers by Uzma Haque Breakdown of academic impact, for papers by Ramesh K. Gupta Breakdown of academic impact, for papers by Johannes W G Jacobs Breakdown of academic impact, for papers by Enrico Fusaro Breakdown of academic impact, for papers by Cristina Iannuccelli Breakdown of academic impact, for papers by Shmuel Tiosano Breakdown of academic impact, for papers by Sofia Pedro Breakdown of academic impact, for papers by Y. Brault Breakdown of academic impact, for papers by Pedro Zarco
Rankless by CCL
2026